GSK Reports Positive Findings for COPD Treatment Studies

Two head-to-head trials comparing the safety of Incruse Ellipta to 2 available bronchodilator treatments used by patients with chronic obstructive pulmonary disease has yielded positive results for GlaxoSmithKline's therapy.

Two head-to-head trials comparing the safety of Incruse Ellipta (umeclidinium) to 2 available bronchodilator treatments used by patients with chronic obstructive pulmonary disease (COPD) has yielded positive results for GlaxoSmithKline’s therapy.

In 12-week multi-center, randomized, blinded study of 1259 patients, the once-daily 62.5 mcg dose of umeclidinium achieved a statistically significant improvement in lung function as 12 weeks compared to a once-daily 18 mcg dose of tiotropium.

The second study was a 12-week multi-center, non-US, randomized, open-label study, which found that the once-daily 62.5 mcg dose of umeclidinium was non-inferior to a once-daily 44 mcg dose of glycopyrronium.

The most common side effects for all 3 treatments were headache and nasopharyngitis.